logo
MEMBERS AREA

Prof. Sébastien PAPOT (University of Poitiers)

At the end of 2018, the Nouvelle Aquitaine region agreed to co-finance with Eva for life the research project "Biological and preclinical studies of new anticancer agents, including some targeting EZH2 / PRC2, in the treatment of highly proliferating hepatoblastoma", led by Prof. Papot and Dr Grosset. The Eva pour la Vie association covered up to 50% of the cost of the purchase of laboratory equipment (in the amount of € 9,000) necessary for the smooth running of this work.
Today, conventional chemotherapy cannot cure the majority of common cancers. Most of the drugs used clinically have little selectivity towards tumor cells and also attack healthy tissue. This non-selective destruction causes severe side effects and often leads to premature discontinuation of treatment.

Recent studies have highlighted some malignant specificities which make it possible to differentiate tumors from healthy tissues. The discovery of these potential targets has led to the development of several therapeutic targeting systems. The objective of these new strategies (vectorized chemotherapies) is to convey a drug to its site of action using a non-toxic vector, then to regenerate its anticancer activity exclusively at the level of the tumor. This approach has several advantages over conventional chemotherapy. Indeed, the selective localization of the cytotoxic molecule in the area to be treated limits the side effects observed during its systemic administration. In addition, the low toxicity of the vector makes it possible to increase the quantity of active agent administered in the organism and thus its concentration at the level of the tumor in order to lead to a more effective treatment.

In this context, the team of Professor Sébastien Papot based at the Poitiers Institute of Chemistry of Media and Materials, has developed new molecules capable of selectively destroying many human tumors (breast, colon, lung, pancreas, head and neck) implanted in mice without causing side effects in animals. Unprecedented results have been obtained in particular for the treatment of pancreatic tumors, a pathology for which there is currently very little therapeutic solution.

Thanks to a collaboration with the team of Doctor Christophe Grosset (INSERM U1035, Bordeaux) and the support of the Eva pour la Vie association, this new therapeutic concept is now being evaluated for the treatment of childhood tumors.

November 2019 update : Click here to read the summary & visuals

En téléchargement

Download the document

WE ALSO SUPPORT ..

Pr Marlène PASQUET (Service d'Hématologie-oncologie pédiatrique, Toulouse) & Justine Thomas

Eva pour la vie soutient le projet d'Activité Physique Adaptée chez l’enfant soigné pour un Cancer et Insulino-Sensibilité APACIS, porté par le Pr Marlène Pasquet, onco-hémato-immunologue pédiatre au sein de l'hôpital des enfants du CHU de Toulouse et Justine Thomas, enseignante en APA et doctorante, ainsi que le recrutement d'un poste d'APA au sein de ce service. 

VIRTU THERAPEUTICS (Nice)

Eva pour la vie & Grandir sans cancer ont, de par leur engagement financier, fortement accéléré le démarrage d’une start-up du médicament liée à la volonté de développer une petite molécule innovante pour le traitement du glioblastome, une tumeur du cerveau de l’adulte et de l’enfant très agressive et généralement incurable. Les dirigeants de cette start-up nous expliquent leurs travaux, perspectives et l'importance de favoriser le développement de petites sociétés axées sur des cancers rares, en particulier les cancers pédiatriques les plus agressifs ...

Dr Fabienne MEGGETTO (INSERM Toulouse)

Dr Fabienne Meggetto is research director at INSERM Toulouse, within a team of excellence whose research work focuses on lymphomas in children. The Eva pour la vie association has decided to provide aid of 50,000 euros for the start of an ambitious and transversal project, which could make it possible to find new therapeutic avenues for lymphomas with a poor prognosis, but also, others. solid tumors such as neuroblastoma. ...

Dr Sébastien APCHER (IGR, Villejuif)

Le Dr Sébastien APCHER est un chercheur INSERM responsable de l’équipe « Epitopes non-conventionnels et réponse immunitaire anti-cancéreuse » à l’INSTITUT GUSTAVE ROUSSY de Villejuif. Il a décidé d’orienter ses travaux de recherche sur les cancers de l’enfant. Eva pour la vie soutient financièrement cette équipe, d'une façon durable. Interview ...

Dr Max PIFFOUX (Center Léon Bérard, Lyon)

Doctor Max PIFFOUX - under the responsibility of the "Apoptosis and cancer" team coordinated by Aurélie DUTOUR at the CLB - is the scientific manager of the following research project: "Autophagic induction as a booster of response to immunotherapies: trial of a new therapeutic class, calorie restriction mimetics, in the pediatric osteosarcoma model ". Eva pour la vie & Aidons Marina have decided to co-finance the launch of this project, by providing a grant of 40,000 euros.

Dr Patrick AUGUSTE (INSERM Bordeaux)

For more than 20 years, this teacher-researcher has been working on cancer. And it's been almost 10 years since he went to kidney cancer or renal cell carcinoma. By joining the team of Dr Christophe Grosset (Inserm, MiRCaDe team), he wanted to use his experience and take a new step forward by working on childhood cancer. He is the initiator of an ambitious project, which involves several surgeons, doctors and international researchers, on the study of nephroblastoma (or Wilms tumor) in children, co-funded by the association Eva pour la vie and Aidons Marina ...

Dr Olivia FROMIGUE (Institut Gustave Roussy)

Resistance to treatment is a major clinical problem, in particular in the case of osteosarcomas, bone tumors affecting children or adolescents. Indeed, chemotherapy, associated with surgery, is the central pillar of current treatment. However, many osteosarcomas are or become resistant to these antiproliferative drugs. Recurrences and / or the appearance of metastases are then frequent. 2 out of 5 patients cannot be cured! Osteosarcoma is therefore a pediatric cancer with a poor prognosis for which it is absolutely necessary to identify ways to counteract resistance to treatment in order to improve the chances of recovery for patients.

Dr Christophe GROSSET (INSERM Bordeaux)

Since 2012, Dr Christophe Grosset has been studying hepatoblastoma, a liver tumor that affects very young children. Today, the main difficulty is to treat patients suffering from metastases or from an inoperable tumor resistant to treatment. With the support of the Eva pour la vie association, the team has set up a new model of hepatoblastoma in the chick embryo which makes it possible to test the effectiveness of new therapeutic molecules (such as microRNAs) and of facilitate the study of these tumors in the laboratory. It has also shown the value of a drug already used in the treatment of certain leukaemias, to treat children with very aggressive liver cancer.

Dr Martin HAGEDORN (INSERM Bordeaux)

Since September 2014, Dr Martin Hagedorn has been leading a team of researchers (Caroline CAPDEVIELLE , Farah RAHAL, Justine CHARPENTIER and Mélissa MENARD) which devotes its research work to the identification of new therapeutic targets in brainstem tumors and to the improvement of its treatment methods. Work recognized by several European scientific teams & experts.

Dr Annie SCHMIDT (INSERM Nice)

The preclinical research project of Dr Alliana Schmid's team focuses on the treatment of pulmonary metastases from osteosarcoma by combinations of immunotherapy.

The aim of this project, which is unique in France, is to evaluate, in a preclinical model of pulmonary metastases from osteosarcoma - a cancer with a poor prognosis which particularly affects adolescents - the effects of a treatment combining two complementary immunotherapy strategies. The Eva pour la vie association is providing funding of 50,000 euros over 3 years, representing the entire cost of this project.

Dr Eddy PASQUIER (CNRS Marseille)

Dr Pasquier's research work mainly focuses on the repositioning of drugs which consists of testing, in new therapeutic indications, drugs already approved by the health authorities. The aim of this work is to identify new therapeutic targets for the most difficult to treat cancers and thus improve the care of patients suffering from these aggressive forms and refractory to treatment . In particular, pediatric cancers (neuroblastoma), brain tumors affecting children as well as adults (glioblastoma, medulloblastoma) as well as certain rare forms of cancer (angiosarcoma).

Dr Marie CASTETS (INSERM Lyon)

The work of the INSERM team co-directed by Dr Marie Castets (CR1 Inserm, HDR) and Dr Jean-Yves Blay (PUPH, HDR) focuses on cell death and cancers. Thanks to the support of Eva pour la Vie (55,000 euros) and other associations, this team is currently developing these lines of research on rhabdomyosarcomas, osteosarcomas and neuroblastomas ...

Epidemiological research

If the development of therapeutic routes adapted to the child is essential (to try to save the children who today, remain without a therapeutic solution and / or to reduce the side effects), we do not forget an equally strong reality: over the past 50 years, the number of children affected by cancer has never declined. Much remains to be done in terms of prevention, both in terms of research and regulation. Eva pour la vie is actively involved by co-financing environmental studies. The first of these, HAPPI, aimed to have the KUDZU SCIENCE laboratory analyze dust samples taken in homes bordering vines - welcoming children or pregnant women - as well as in a primary school classroom.

Andre Cicolella (RES, Paris)

André Cicolella is a French chemist, toxicologist and researcher in environmental health, specialist in health risk assessment. Eva pour la vie co-financed, with the REGARDS collective, the French transposition of a study carried out in Denmark from cancer and drug consumption registers, which had highlighted a risk multiplied by 3 of osteosarcomas and by 2 of Hodgkin's and non-Hodgkin's lymphomas in the event of exposure via drugs using DEP phthalate (DiEthyl Phthalate) in gastro-resistant drugs.